Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)
Sponsor: Merck Sharp & Dohme LLC
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics (PK) and preliminary efficacy of oral nemtabrutinib in Chinese participants at least 18 years of age who have Relapsed/Refractory hematologic malignancies.
Official title: A Phase 1 Clinical Study to Investigate the Safety, Pharmacokinetics and Efficacy of MK-1026 in China Participants With Relapsed or Refractory Hematologic Malignancies
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2022-06-09
Completion Date
2027-04-30
Last Updated
2025-08-15
Healthy Volunteers
No
Conditions
Interventions
Nemtabrutinib
Nemtabrutinib tablets will be administered orally QD.
Locations (5)
Guangdong Provincial People's Hospital-hematology department ( Site 1002)
Guangzhou, Guangdong, China
SUN YAT-SEN UNIVERSITY CANCER CENTRE-Internal medicine ( Site 1007)
Guangzhou, Guangdong, China
Henan Cancer Hospital-hematology department ( Site 1003)
Zhengzhou, Henan, China
Hunan Cancer Hospital ( Site 1004)
Changsha, Hunan, China
Institute of hematology&blood disease hospital-Hematology ( Site 1001)
Tianjin, Tianjin Municipality, China